About Mimetas
Mimetas is a company based in Leiden (Netherlands) founded in 2013 by Paul Vulto. Mimetas has raised $28.9 million across 21 funding rounds from investors including Cathay Financial Holdings, HHS and European Union. Mimetas operates in a competitive market with competitors including Emulate, CN Bio, AxoSim, Nortis and NETRI, among others.
- Headquarter Leiden, Netherlands
- Founders Paul Vulto
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$28.9 M (USD)
in 21 rounds
-
Latest Funding Round
$272.82 K (USD), Grant
Sep 01, 2022
-
Investors
Cathay Financial Holdings
& 9 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of Mimetas
Unlock access to complete
Unlock access to complete
Funding Insights of Mimetas
Mimetas has successfully raised a total of $28.9M across 21 strategic funding rounds. The most recent funding activity was a Grant round of $272.82 thousand completed in September 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Mimetas
Mimetas has secured backing from 10 investors, including institutional and venture fund investors. Prominent investors backing the company include Cathay Financial Holdings, HHS and European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked | |
|
Sustainable investing in conscious consumer, energy transition, and healthy living sectors.
|
Locked | Locked | Locked | |
|
Sector-agnostic VC firm investing primarily in the Netherlands
|
Locked | Locked | Locked |
Investor details for Mimetas
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Mimetas
Investment portfolio details for Mimetas
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Mimetas
Detailed financials for Mimetas
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Mimetas Comparisons
Peer comparison for Mimetas
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Mimetas
Mimetas operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Emulate, CN Bio, AxoSim, Nortis and NETRI, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Developer of in vitro models for drug development
|
|
| Locked | Locked | Locked |
Organ-on-a-chip platforms are developed for drug discovery applications.
|
|
| Locked | Locked | Locked |
Nerve-on-a-chip technology is advanced by AxoSim for drug development improvement.
|
|
| Locked | Locked | Locked |
Small human tissue segments are generated in microfluidic chips.
|
|
| Locked | Locked | Locked |
Microfluidic devices are developed for industrial applications and brain-on-a-chip models.
|
Detailed competitors of Mimetas
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Mimetas
Complete news archive for Mimetas
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Mimetas
Mimetas was founded in 2013 and raised its 1st funding round 1 year after it was founded.
Mimetas is headquartered in Leiden, Netherlands. It is registered at Leiden, South Holland, Netherlands.
Paul Vulto is the current CEO of Mimetas. They have also founded this company.
Mimetas is a funded company, having raised a total of $28.9M across 21 funding rounds to date.
Mimetas was founded in 2013 in Leiden, Netherlands, where microfluidics-based organ-on-a-chip tissue models are developed for evaluating drugs, chemicals, and food components. Products such as OrganoPlates, OrganoReady, OrganoTEER, and OrganoFlow are utilized as culture plates for in-vitro tissue culturing. These enable the screening of 3D organ and tissue models to predict toxic side effects, assess drug efficacy, and validate disease, toxicology, and transport models in the biotechnology sector.
Mimetas's top competitors include Emulate, CN Bio and Cellbox Labs.
Mimetas has 10 investors. Key investors include Cathay Financial Holdings, HHS, European Union, Oost NL, and InnovationQuarter.